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Abstract
 
A characteristic feature of rheumatoid arthritis is the abundance of inflammatory cells in the
diseased joint. Two major components of this infiltrate are neutrophils in the synovial fluid and
macrophages in the synovial tissue. These cells produce cytokines including tumor necrosis fac-
tor 
 
  
 
and other proinflammatory mediators that likely drive the disease through its effector
phases. To investigate what mechanisms underlie the recruitment of these cells into the syn-
ovial fluid and tissue, we performed expression analyses of chemoattractant receptors in a re-
lated family that includes the anaphylatoxin receptors and the formyl-MetLeuPhe receptor. We
then examined the effect of targeted disruption of two abundantly expressed chemoattractant
receptors, the receptors for C3a and C5a, on arthritogenesis in a mouse model of disease. We
report that genetic ablation of C5a receptor expression completely protects mice from arthritis.
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Introduction
 
Rheumatoid arthritis (RA)
 
* 
 
is a chronic inflammatory dis-
ease characterized by the infiltration of T cells, B cells, mac-
rophages, and neutrophils into the synovial lining and fluid
of the periarticular spaces. The infiltrating cells produce
abundant cytokines, dominated by TNF
 
  
 
and IL-1
 
 
 
,
which stimulate infiltrating cells and resident fibroblast-like
synoviocytes (1, 2). These interactions lead to fibroblast hy-
perproliferation and formation of an invasive pannus tissue
that produces collagenases and stromelysins, ultimately re-
sulting in the destruction of neighboring cartilage and bone
(3). The arthritic process apparently arises through a series
of discrete stages. The activation and expansion of antigen-
specific T and B cells in the synovium is believed to play a
role in the initiation of the disease (4). Subsequently, in the
“effector” phase, macrophages, neutrophils, and lympho-
cytes are recruited to the joint where, in concert with resi-
dent fibroblasts, they mediate the chronic destructive events
through the release of cytokines, proteases, and other medi-
ators (1, 2). However, the mechanisms that regulate these
effector responses remain to be fully elucidated and it is not
clear which chemokines and chemoattractants are primarily
responsible for the localization of cells into the synovium.
Inflammatory cell recruitment into the synovial fluid and
the synovial tissue occurs as a result of the production of
chemoattractants by activated macrophages, synovial fibro-
blasts, and other cells in the inflamed joint. In recent years,
attention has been focused on chemokine family members
such as monocyte chemoattractant protein 1, RANTES,
macrophage inflammatory protein (MIP)-1
 
 
 
, MIP-2
 
 
 
, and
epithelial neutrophil activator (ENA)-78 (3). Chemokines
signal through a number of related G protein–coupled re-
ceptors (GPCRs) that are expressed on distinct leukocyte
cell populations, including the cells recruited to the joint
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during arthritogenesis. Given the large number of potential
recruitment pathways that could contribute to joint inflam-
mation, it has been difficult to determine which, if any,
play unique roles that cannot be compensated by other
chemokines and their receptors. Studies in animal models
have suggested an important role for certain chemokine
interactions with their receptors. For example, experimen-
tal arthritis can be partially ameliorated with modified
RANTES (met-RANTES) and monocyte chemoattractant
protein 1 antagonists (5–7). As these chemokines are pro-
miscuous in binding to several distinct chemokine recep-
tors, the relative importance of their cognate receptors in
cell recruitment remains to be fully defined.
A second family of chemoattractant molecules, which
signal through a related family of GPCRs, is comprised of
complement fragments and bacterial peptides such as C3a,
C5a, and formyl-MetLeuPhe (8–10). Like the chemokine
family, a number of these chemotactic molecules are
present in the synovial tissue and/or synovial fluid of RA
patients (9). The presence of elevated anaphylatoxin C3a
and C5a levels is but one of several indications that the
complement system is hyperactive in RA patients. For ex-
ample, it has long been appreciated that antibody-driven
inflammatory responses, through activation of the comple-
ment cascade or Fc-dependent cellular activation, play a
crucial role in arthritis. In this context, the synovial tissue
and fluid of RA patients frequently contain abundant au-
toantibodies such as rheumatoid factor (11). In addition, ar-
thritis can be induced in rodents by passive transfer of anti-
collagen antibodies (12). The potential pathogenic role of
autoantibodies has been further highlighted in recent years
with the advent of the K/BxN arthritis model, in which
disease can be induced by the transfer of anti–glucose-6-
phosphate isomerase (GPI) autoantibodies (13).
The C5a receptor (C5aR) is recognized to be a potent
chemoattractant receptor on neutrophils, monocytes,
macrophages, and eosinophils (14). The liberation of C5a
at sites of complement activation therefore leads to the re-
cruitment of these cell types into sites of infection or au-
toantibody deposition. The C5aR is also present on a va-
riety of other cell types, including bronchial epithelial and
smooth muscle cells as well as endothelial cells and hepa-
tocytes, where expression has been implicated in cell acti-
vation and the induction of proinflammatory mediators
(15). The C3a receptor (C3aR) is also present on an array
of cell types, including inflammatory cells as well as resi-
dent lung epithelium and smooth muscle cells. The C3aR
and C5aR anaphylatoxin receptors are perhaps best
known for their function as activators of histamine re-
lease, bronchoconstriction, and vasodilation (15). As such,
the C3aR was recently implicated in the effector phase of
asthma (16, 17). However, the roles of these receptors in
cell recruitment pathways during the course of arthritic
inflammation have not been delineated. Here, we report
that genetic deletion of the C5aR completely protects
mice from arthritis induced with anticollagen antibodies,
indicating a central role for C5a-dependent cell recruit-
ment and activation in the initiation of arthritis in this
 
model. These data raise the possibility that drugs and bio-
therapeutics targeting the C5aR may provide a novel
strategy for therapeutic intervention to disrupt the effec-
tor phase of RA.
 
Materials and Methods
 
Mice.
 
The generation and characterization of C3aR
 
 
 
/
 
  
 
and
C5aR
 
 
 
/
 
  
 
mice has been previously described (16, 18). C3aR
 
 
 
/
 
 
 
and C5aR
 
 
 
/
 
  
 
mice backcrossed three and four generations, re-
spectively, onto a BALB/c background and littermate controls
were used for all experiments described. Animal studies were per-
formed according to institutional and National Institutes of
Health guidelines for animal use and care.
 
Human Cell Isolation and Culture.
 
Normal human peripheral
blood monocytes were isolated using CD14-MicroBeads and
magnetic cell separation technology according to the manufac-
turer’s instructions (Miltenyi Biotec). Macrophages were derived
by culturing purified monocytes for 10 d in the presence of 100
ng/ml GM-CSF (Pierce Chemical Co.). Granulocytes were iso-
lated from peripheral blood via Ficoll density gradient separation.
Isolated cell populations were cultured in RPMI 1640 medium
(Invitrogen) containing 10% fetal bovine serum (Invitrogen) for 4
or 24 h in the presence of one of the following stimuli: 1 
 
 
 
g/ml
 
Escherichia coli
 
 026:B6 LPS (Sigma-Aldrich), 5 
 
 
 
g/ml recombi-
nant human CD40L (PeproTech), or 100 ng/ml recombinant
human TNF
 
  
 
(PeproTech). RNA was extracted and used in
TaqMan
 
® 
 
analyses as described below.
 
Immunohistochemistry.
 
Human RA synovial tissue was ob-
tained as discarded material from joint replacement surgery. 5-
 
 
 
m
sections of snap frozen tissue blocks were fixed in acetone
and incubated in 0.3% goat serum (Vector Laboratories)/0.3%
hydrogen peroxide in PBS for 5 min. Sections were incubated in
PBS/5% goat serum for 30 min followed by anti-C5aR (BD
Biosciences) or control rabbit IgG (Dako) for 1 h at room tem-
perature. The slides were developed using the VECTASTAIN
 
®
 
Elite ABC Rabbit IgG kit and the AEC Peroxidase Substrate kit
(Vector Laboratories) and counterstained in Mayer’s hematoxy-
lin (Poly Scientific). To detect IgG deposition, mouse joints
were fixed and decalcified in 4% paraformaldehyde/10% EDTA
(both from Sigma-Aldrich) for 14 d and embedded in optimum
cutting temperature for sectioning. 6-
 
 
 
m sections were incu-
bated with FCS to block Fc receptor binding followed by bio-
tinylated rat anti–mouse IgG (Dako). Staining was revealed using
StreptABCComplex/horseradish peroxidase detection (Dako)
according to the manufacturer’s instructions. To detect C3 and
C1q deposition, joints were fixed for 4 d in buffered 10% forma-
lin (Fisher Scientific), decalcified for 2 wk in 5% formic acid
(Sigma-Aldrich), and processed for paraffin embedding. 6-
 
 
 
m
sections were incubated with FCS followed by anti-C3, anti-
C1q (both from Connex), or control rat IgG (Dako). Sections
were then incubated with biotinylated rabbit anti–rat IgG and
staining was revealed using StreptABCComplex/horseradish
peroxidase detection. All slides were counter stained with hema-
toxylin (Poly Scientific).
 
Antibody-induced Experimental Arthritis.
 
10–12-wk-old
C3aR
 
 
 
/
 
  
 
or C5aR
 
 
 
/
 
  
 
mice and wild-type littermates (five mice
per group) were immunized intravenously with 4 mg Arthrogen-
collagen-induced arthritis (CIA) type II collagen-specific mAbs, a
mixture of four mAbs that recognize individual epitopes within
the CB11 fragment of type II collagen (Chemicon International,
Inc.). 48–72 h later, mice were administered 25 
 
 
 
g LPS (Chemi- 
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con International, Inc.) intraperitoneally and monitored for clini-
cal signs of arthritis twice weekly for 14 d. Arthritis indications
were scored as follows: 0
 
   
 
normal, 1 
 
  
 
swelling in phalangeal
joints only, 2 
 
  
 
severe local swelling or moderate swelling over
whole paw, 3 
 
  
 
severe swelling over whole paw, and 4 
 
  
 
anky-
losis. Scoring was performed by a blinded observer.
 
Histological Analysis of Arthritis.
 
Knees, hind paws, and fore-
paws from one side of each mouse were fixed for 4 d in buffered
10% formalin (Fisher Scientific), decalcified for 2 wk in 5% for-
mic acid (Sigma-Aldrich), and processed for paraffin embedding.
6-
 
 
 
m sections were stained with hematoxylin and eosin (H&E;
Poly Scientific) and scored by a blinded observer for inflamma-
tion, pannus formation/cartilage loss, and bone erosion (see Table
II). Severity was scored in a range from 0–4 for each parameter
and the degree of involvement was determined by the percentage
of articular surfaces affected by pannus formation.
 
RNA Extraction and PCR Analysis.
 
Total RNA was prepared
from tissues and cells by a single step extraction method using
RNA STAT-60 (Tel-Test, Inc.). After DNase I (QIAGEN)
treatment, cDNA was synthesized using Multiscribe Reverse
Transcription Kit (Applied Biosystems). Gene expression was
measured by TaqMan
 
® 
 
real-time PCR (Applied Biosystems) ac-
cording to the manufacturer’s protocols. Probes and primer sets
for mouse GAPDH and mouse IL-1
 
  
 
were purchased from Ap-
plied Biosystems. Sequences of all other primers and probes are
listed in Table I.
Target gene probes were labeled with 6-carboxyfluorescein
(FAM) and the internal reference probes, human 
 
 
 
2
 
-microglobu-
lin and rodent GAPDH, were labeled with VIC. PCR reactions
contained the forward and reverse primers (200 nM) and the
probe (100 nM) for 
 
 
 
2
 
-microglobulin or GAPDH and the for-
ward and reverse primers (600 nM) and probe (200 nM) for the
gene of interest. The experiments were performed on an ABI
PRISM 7700 Sequence Detection System (Applied Biosystems)
using the following conditions: 2 min at 50
 
 
 
C, 10 min at 95
 
 
 
C,
followed by two-step PCR for 40 cycles of 95
 
 
 
C for 15 s fol-
lowed by 60
 
 
 
C for 1 min. The number of PCR cycles needed for
FAM and VIC fluorescence to cross a threshold of a statistically
significant increase in fluorescence (Ct 
 
  
 
threshold cycle) was
measured using Applied Biosystems software. Relative target
gene expression was determined using this formula: Relative Ex-
pression 
 
  
 
2
 
-(
 
  
 
CT) 
 
where 
 
  
 
CT 
 
  
 
(Ct
 
target gene 
 
– Ct
 
reference gene 
 
in
experimental cDNA sample) – (Ct
 
target gene 
 
– Ct
 
reference gene 
 
in mock
reverse transcribed RNA sample).
 
Myeloperoxidase (MPO) Assay.
 
Frozen joints were pulverized
with a Bessman tissue pulverizer (BioSpec Products) on dry ice
placed in 4 ml MPO buffer (50 mM Na
 
2
 
HPO
 
4
 
/0.5% hexadecyl
trimethyl ammonium bromide/10 mM EDTA, pH 5.4) and ho-
mogenized with three 30-s bursts with a PowerGen tissue ho-
mogenizer (Fisher Scientific). The samples were subjected to
three rounds of freeze/thaw at 
 
 
 
80
 
 
 
C. The homogenate was
sonicated briefly in a water bath sonicator at maximum intensity.
Insoluble material was removed by centrifugation in a microcen-
trifuge at 14,000 rpm for 5 min. Total protein content of the su-
pernatant was determined using the bicinchoninic acid protein
assay (Pierce Chemical Co.) and MPO activity was measured as
follows. Samples were plated in 96-well tissue culture plates
(Fisher Scientific) in a volume of 25 
 
 
 
l/well. 25 
 
 
 
l 1.67 mg/ml
O-dianisidine (Sigma-Aldrich) in 50 mM Na
 
2
 
HPO
 
4
 
, pH 5.4,
was added to each well. 200 
 
 
 
l 0.009% H
 
2
 
O
 
2 
 
in 50 mM
Na
 
2
 
HPO
 
4
 
, pH 5.4, was then added to each well and incubated
for 10 min at room temperature. The A
 
450 
 
was measured and
background subtracted for wells containing MPO buffer alone.
The A
 
450
 
/mg total protein was then calculated to determine the
relative MPO activity.
 
Results
 
Expression of the C3aR and C5aR in Human Cells and in
RA Synovium.
 
To identify chemoattractant receptors ex-
pressed abundantly on key inflammatory cell types involved
in arthritic pathogenesis, we performed a quantitative
mRNA expression analysis using normal peripheral blood-
derived monocytes, macrophages, and granulocytes. We
extracted RNA from each of these populations before and
after activation with relevant stimuli, synthesized cDNA,
and performed TaqMan
 
®
 
 real-time PCR analysis of the
anaphylatoxin receptors C3aR and C5aR and the formyl-
MetLeuPhe receptor-like GPCRs, FPRL1, and FPRL2.
Together, these receptors form a chemoattractant receptor
subfamily of GPCRs, although the biologic function and
ligands for FPRL1 and FPRL2 have yet to be fully delin-
eated. Of these receptors, C5aR had the highest levels of
expression in granulocytes, monocytes, and macrophages
(Fig. 1 A). Expression of C5aR appeared to be increased in
granulocytes after a 4-h stimulation with TNF
 
 
 
. However,
expression in monocytes and macrophages was not appre-
ciably regulated by cell activation. C3aR expression was
also notable in these three cell populations and like the
C5aR, expression was augmented transiently in TNF
 
 
 
-
stimulated granulocytes. In comparison, FPRL1 and FPRL2
were expressed at lower levels (Fig. 1 A). Given the abun-
dant relative expression of C3aR and C5aR on these cell
types, we performed additional expression analyses of these
two receptors in diseased human tissue.
To examine the distribution and expression of the C3aR
and C5aR in inflamed human synovium, we performed an
immunohistochemical analysis on frozen sections of human
RA synovium from multiple individuals. Pronounced
staining of both receptors was observed in the intimal layer,
consistent with localization to macrophage-like synovio-
cytes, as well as scattered throughout the subintimal region
(Fig. 1 B). Of the two receptors, C5aR was consistently
more pronounced in expression, although this may in part
reflect differences in avidities between the two antibodies.
Immunohistochemistry with an anti-CD68 mAb on serial
sections showed a very similar pattern of expression, with
intense staining in the intimal layer and scattered positive
subintimal cells. Thus, it is likely that the majority of
C3aR
 
  
 
and C5aR
 
  
 
cells in the RA synovium are mac-
rophages, although it is possible that C3aR
 
  
 
and C5aR
 
 
 
infiltrating neutrophils and other granulocytes are also
present. In addition, C5aR was clearly detected on endo-
thelial cells lining the blood vessels within synovial tissues
(Fig. 1 B). The abundance of expression of these receptors
in inflamed synovial tissue together with the high levels of
expression on three major effector cell populations
prompted us to examine the role of the C3aR and C5aR
in the recruitment of inflammatory cells in a rodent model
of arthritis. 
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Inflammatory Gene Regulation in Anticollagen Antibody-
induced Arthritis.
 
To characterize the inflammatory changes
that occur during the course of anticollagen mAb-induced
arthritis, we isolated joints from mice 24, 48, and 72 h and
5, 7, 9, 11, and 13 d after intravenous injection with an ar-
thritogenic antibody cocktail. At each time point, we as-
sessed joint swelling and then froze isolated joints for subse-
quent expression analyses. We used quantitative PCR to
measure the relative expression and changes in transcription
of a panel of inflammatory markers, including markers for
the major immune cell subsets. Most markers examined
showed a consistent pattern of induction 72 h after mAb
injection (24 h after an intraperitoneal LPS boost given to
the animals; Fig.1 C). In particular, IL-1
 
  
 
and matrix me-
talloproteinase (MMP)-3 (stromelysin 1) showed marked
induction from very low basal levels to high levels that
were sustained to the last time point examined, 13 d after
mAb injection. CD4 and CD68 mRNA levels increased
 
Table I.
 
Sequence of Primers and Probes
 
Mouse Forward Primer Reverse Primer
C3aR 5
 
 
 
-GGCCCTGGGAACCTAAGC-3
 
 
 
5
 
 
 
-TGAGAGTCGCCAAATTGTCTAAAG-3
 
 
 
C5aR 5
 
 
 
-GGGTAGCTTCCCCAAAGAGAA-3
 
 
 
5
 
 
 
-AGGAGGAAGGTGTAGCAGATGTTTA-3
 
 
 
TNF
 
 
 
5
 
 
 
-ACAAGGCTGCCCCGACTAC-3
 
 
 
5
 
 
 
-CGGCAGAGAGGAGGTTGACTT-3
 
 
 
MMP-3 5
 
 
 
-TGAGTCTTTGTGAAAGGAAGTGCTT-3
 
 
 
5
 
 
 
-ATCCTTTGACAACTTGACGTTGAC-3
 
 
 
CD4 5
 
 
 
-TCTGCATCCTCTGCTGTGTCA-3
 
  5 -AGCCTCTTGATCTGAGACATTCG-3 
CD19 5 -AAACCCAATTAGCCACTCAAATTCT-3  5 -CCAGGATGTACTCAGACCTCAGTTC-3 
CD68 5 -TGACCTGCTCTCTCTAAGGCTACA-3  5 -AGGACCAGGCCAATGATGAG-3 
OPG 5 -ATCTCGGCCACTCGAACCT-3  5 -CAATCTCTTCTGGGCTGATCTTC-3 
OPGL 5 -GCTTATGAAAAACTTACACGTGAGCTAT-3  5 -TGGCATCCTCTTAATTTCAAGGTT-3 
ENA-78 5 -TTCAGAAAATATTGGGCAGTGACA-3  5 -CTATTGAACACTGGCCGTTCTTT-3 
MIP-1  5 -TCATCGTTGACTATTTTGAAACCAG-3  5 -GCCGGTTTCTCTTAGTCAGGAA-3 
MIP-2  5 -CAAGAACATCCAGAGCTTGAGTGT-3  5 -CTTGAGAGTGGCTATGACTTCTGTCT-3 
ICAM-1 5 -CCCACAGTGGGTCGAAGGT-3  5 -GATCCTCCGAGCTGGCATT-3 
VCAM-1 5 -GTATTAAAGTCTGTGGATGGCTCGTA-3  5 -TCAGTCTTAGATTCACACTCGTATATGC-3 
E-selectin 5 -GCTAGGCAGACATATTGGCTTTATC-3  5 -GGACACAGAACACAATGTTCAAGAAT-3 
Human Forward Primer Reverse Primer
C5aR 5 -AGGTGGGAGAATTGCTCGAA-3  5 -AGAGTGCAGTGGTGCGATCA-3 
 2m 5 -CACCCCCACTGAAAAAGATGA-3  5 -CTTAACTATCTTGGGCTGTGACAAAG-3 
Mouse Probe
C3aR 5 -CACATGTCATCCATCACTGTTCACCTGAGAA-3 
C5aR 5 -AAACCCACCATCAGCCGCAGGA-3 
TNF  5 -CCTCACCCACACCGTCAGCCG-3 
MMP-3 5 -CTCCTGTTTGGTTCTGCCATAGCACATG-3 
CD4 5 -CCGGCACCAACAGCGCCA-3 
CD19 5 -TTCCTATCCCACACAAGGGCCGG-3 
CD68 5 -CCCGAAGTGTCCCTTGTCAGGCA-3 
OPG 5 -CAGGCAGGCTCTCCATCAAGGCA-3 
OPGL 5 -TGGTCTAACCCCTGGACATGTGCCA-3 
ENA-78 5 -CACTGCGAGTGCATTCCGCTTAGCT-3 
MIP-1  5 -AGCCTTTGCTCCCAGCCAGGTGTC-3 
MIP-2  5 -CCCCCAGGACCCCACTGCG-3 
ICAM-1 5 -CCACCCACCCCGCAAGTCCAAT-3 
VCAM-1 5 -CCAGGCACAGCTGCAGGATGCC-3 
E-selectin 5 -TCGGCAGCCACTGAATCCCATG-3 
Human Probe
C5aR 5 -TGGAGGTGGAGGTTGTGGTGAGCC-3 
 2m 5 -ATGCCTGCCGTGTGAACCACGTG-3 1465 Grant et al.
substantially and with similar kinetics, reflecting the influx
of T cells and macrophages, respectively, during the devel-
opment of arthritis. Similarly, C3aR and C5aR expression
dramatically increased 72 h after mAb administration, likely
indicating the influx of neutrophils and monocyte/macro-
phage lineage cells, the principal immune cell subsets on
which those receptors are found. In addition, the increase
in C5aR expression may reflect augmented transcription in
resident tissue macrophages and endothelial cells. Os-
teoprotegerin ligand (OPGL) message levels were also in-
Figure 1. Expression of C5aR in human RA
tissue and in a mouse model of arthritis. (A) Quan-
titative PCR analysis of C5aR, C3aR, FPRL1, and
FPRL2 in untreated (UnTx) or activated (LPS,
TNF , IFN , or CD40L for 4 or 24 h) normal
human peripheral blood monocytes (MONO),
monocyte-derived macrophages (M ), and periph-
eral blood–derived granulocytes (GRAN). Data
plotted are the mean   SD of the relative expres-
sion of each receptor in RNA samples pooled from
three different donors using  2-microglobulin as a
reference. The results are representative of three in-
dependent experiments. (B) Immunohistochemis-
try analysis of human RA synovial tissue stained
with anti-C5aR, anti-C3aR, anti-CD68, or con-
trol IgG. Data shown are representative of expres-
sion patterns observed of four RA synovial tissues.
(C) Quantitative PCR analysis of C5aR, C3aR,
and inflammatory marker expression in mouse joint
RNA during the course of arthritis induction. Data
are the mean   SD of the relative expression of
each gene in two joints.1466 The C5a Receptor Is Essential for the Effector Phase of Experimental Arthritis
creased, presumably a reflection of the influx of T cells into
the joint space, whereas osteoprotegerin, expressed mainly
by resident chondrocytes and osteoclast precursors, re-
mained relatively stable. In contrast, the expression of
CD19, a marker for B lineage cells, did not change dramat-
ically, indicating that B cells are not a major cell subset re-
cruited into joints in this animal model (unpublished data).
C5aR-deficient Mice Are Resistant to Arthritis Induction.
As C3aR and C5aR expression were clearly up-regulated
during the course of disease in this model of arthritis, we
examined the effect of deleting expression of each of these
receptors on disease induction and severity. Throughout
the 14-d course of arthritogenesis, the paw swelling scores
of C3aR /  mice were nearly identical to those of C3aR / 
littermates (Fig. 2 A). Histological analyses of joint sec-
tions taken from C3aR /  and C3aR /  animals 2 wk after
arthritis induction revealed similar degrees of inflammatory
cell recruitment, fibroblast proliferation, and cartilage and
bone destruction (Fig. 2 B). Thus, deletion of the C3aR
appears to have no substantial effect on this animal model
of arthritis. However, strikingly, in three independent ex-
periments C5aR /  mice were completely protected from
disease induction as assessed by paw swelling (n   5 per ex-
periment). In contrast, wild-type animals consistently and
synchronously developed arthritis 72 h after inoculation
with the arthritogenic antibodies (Fig. 2 A). We removed
Figure 2. C5aR    mice are protected from arthritis induction. (A) Mean clinical scores at
days 0, 3, 4, 7, 9, and 14 of arthritis development in C3aR /  (bottom) or C5aR /  (top) mice
and their littermate controls. Each group of mice consisted of five animals. The results shown
are representative of three separate experiments. (B) H&E stained joint sections from represen-
tative C3aR / , C3aR / , C5aR / , and C5aR /  mice 14 d after mAb transfer. Cartilage (C)
surfaces are indicated in the images as are regions of pannus tissue (P) comprised of proliferating
synoviocytes and infiltrating leukocytes. (C) Joints from naive C5aR /  mice. Ab-injected
C5aR /  or Ab-injected C5aR /  mice were stained with an antibody against mouse IgG to
detect deposition (brown staining, top). Inflamed joints from C5aR /  mice 14 d after Ab
transfer were stained with control IgG, anti-C3, or anti-C1q antibodies to detect the accumula-
tion of complement components on the cartilage surfaces (bottom).1467 Grant et al.
joints from animals 14 d after arthritis induction and exam-
ined them for histological changes (Table II). H&E stained
sections from wild-type arthritic mice had large, obvious
inflammatory cell infiltrates. Pannus formation was also ev-
ident with expansion of the synovial membrane and prolif-
eration of the synovial lining fibroblasts. Lastly, erosion of
the cartilage and bone surfaces was apparent, accompanied
by invasion of the pannus tissue into the bone space, remi-
niscent of the severe changes associated with human RA.
The most severe cases showed complete destruction of the
normal joint architecture. Consistent with the clinical ob-
servation that C5aR /  animals had reduced gross inflam-
mation, joint sections from these animals appeared normal
with thin synovial lining, only rare infiltrating inflamma-
tory cells, and normal smooth cartilage surfaces indicating a
lack of cartilage- and bone-erosive processes (Fig. 2 B).
Evidence for Antibody Deposition and Complement Activa-
tion. The failure of C5aR /  mice to develop arthritis
could be due to prevention of the localization of anticol-
lagen antibodies to the joint in the absence of the receptor.
To exclude this possibility, we analyzed joint sections from
C5aR /  and C5aR /  animals after anticollagen antibody
transfer for deposition on the cartilage surfaces. As ex-
pected, we observed no antibody deposition in joints from
naive animals. In contrast, we readily detected antibody
deposition in joints from both C5aR /  and C5aR / 
mice (Fig. 2 C, top). To additionally examine whether an-
ticollagen deposition on articular surfaces in this model in-
duces complement activation, we analyzed joint sections
from naive and arthritic mice for the presence of C3, a
marker of activation of both alternative and classical path-
ways, and C1q, a marker of classical pathway activation.
We detected both C3 and C1q deposition on cartilage in
diseased joints (Fig. 2 C, bottom). In comparison, low
background staining was observed in sections stained with a
control antibody (Fig. 2 C) and in joints from naive mice
(not depicted). Thus, in this acute effector model of arthri-
tis, the deposition of autoreactive antibodies on articular
cartilage leads to the activation of the classical pathway of
complement activation.
Quantitative Assessment of Joint Inflammation in C5aR-defi-
cient Mice. Although mice lacking the C5aR were clearly
much less sensitive to arthritis induction than their wild-
type littermates, we felt it important to quantitatively assess
the influx of inflammatory cells into the joint as well as the
induction of cytokines and proteases associated with arthri-
tis progression. Therefore, we isolated RNA from the
joints of C5aR /  and C5aR /  animals 14 d after arthritis
induction. We then compared the relative expression of
CD4, CD68, and CD19 via quantitative PCR to assess the
extent of the influx of T cells, macrophages, and B cells, re-
spectively. C5aR /   mice showed clear increases in
mRNA levels of CD4 and CD68 relative to naive joints,
consistent with the influx of inflammatory cells into the
joints (Fig. 3). In contrast, mRNA levels in the joints from
C5aR /  animals after arthritis induction were significantly
lower than in wild-type animals. In fact, the levels of these
markers remained within the range of naive animals, indi-
cating a profound reduction in the number of T cells and
macrophages recruited into the joint. Similarly, we ana-
lyzed the level of expression of several inflammatory mark-
ers, including IL-1 , TNF , and MMP-3. The levels of
mRNA for each of these genes were significantly increased
in joints from arthritic wild-type mice in comparison to na-
ive joints (Fig. 3). As before, mRNA levels in C5aR /  an-
imals remained at baseline levels 2 wk after injection of the
arthritogenic mAbs. Similarly, we observed that OPGL
mRNA levels increased substantially in wild-type mice dur-
ing the course of disease, yet failed to change in C5aR / 
animals. This difference is likely to reflect the reduced os-
teoclastogenesis and bone erosion in C5aR /  mice.
Reduced Influx of Neutrophils into Joints of C5aR-deficient
Mice. The C5aR is expressed on and mediates chemotaxis
of neutrophils, monocytes, and macrophages. In addition
to C5a, other mediators of neutrophil recruitment, includ-
ing the chemokines MIP-1 , MIP-2, and ENA-78, have
been found at elevated levels in RA synovial tissue, syn-
ovial fluid, and peripheral blood. To assess the effect of
C5aR deletion on the recruitment of neutrophils into the
joint space after arthritis induction, we measured the rela-
tive expression of several chemokines known to recruit
neutrophils via receptors other than the C5aR. In wild-
type animals, MIP-1 , MIP-2 , and ENA-78 levels were
strongly induced during the course of arthritis develop-
ment. C5aR /  animals, however, failed to show induc-
tion of any of these chemoattractants above the back-
ground levels present in joints from naive mice (Fig. 4 A).
To directly assess the influx of neutrophils into the joints of
Table II. Histological Analysis of C5aR    and C5aR    Joints
Inflammation Cartilage Bone
Rear Fore Rear Fore Rear Fore Total Mean
C5aR    14 3 34342 1
21.25
C5aR    24 4 34342 2
C5aR    34 4 34332 1
C5aR    44 4 44232 1
C5aR    11 1 00002
2.25
C5aR    21 1 00002
C5aR    31 1 00002
C5aR    41 2 00003
H&E stained joint sections were examined for degree of inflammatory
cell infiltrate, pannus/cartilage involvement, and bone destruction using a
scale of severity ranging from 0 (normal) to 4 (severe). The data pre-
sented are from the fore and rear paws of four C5aR /  mice and four
C5aR /  mice and are representative of the results observed in three
separate experiments.1468 The C5a Receptor Is Essential for the Effector Phase of Experimental Arthritis
C5aR /  and C5aR /  mice, we prepared protein extracts
from frozen joints 2 wk after arthritis induction. We then
measured the levels of MPO enzyme activity in the joint
extracts as a measure of neutrophil influx. A significant de-
crease (fourfold, P   0.005) in levels of MPO was observed
in the C5aR /  animals relative to wild-type littermates,
Figure 3. Quantitative assessment of inflamma-
tory markers in C5aR     and C5aR     mouse
joints. RNA was extracted from the joints of naive
wild-type or mAb-injected C5aR /  ( /  A) or
mAb-injected C5aR /  ( /  A) mice 13 d after
mAb transfer and analyzed via quantitative PCR
analysis for the indicated genes. The levels of IL-1 ,
CD68, TNF , CD4, MMP-3, and OPGL were
significantly reduced in the joints from C5aR / 
mice injected with the arthritogenic antibodies
( /  A) compared with injected C5aR /  mice
( /  A; P   0.0001, Student’s t test). Data are the
mean   SD of the relative expression of each gene
in ten joints each from naive mice or from mAb-
injected C5aR /  or C5aR /  mice. The results are
representative of three independent experiments.
Figure 4. Decrease in neutrophilia, chemokines, and adhesion receptor induc-
tion in C5aR    mice. (A) Neutrophil chemotactic factors ENA-78 (P  
0.0001, Student’s t test), MIP-1  (P   0.0001), and MIP-2 (P   0.0001), and
adhesion molecules ICAM-1 (P   0.002), VCAM-1 (P   0.0001), and E-selec-
tin (P   0.0001) were significantly reduced in joints from C5aR /  mice in-
jected with the arthritogenic antibodies ( /   A) compared with injected
C5aR /  mice ( /  A). Quantitative PCR data are expressed as described in
Fig. 3. (B) Neutrophilia is reduced in joints from C5aR /  mice injected with
the arthritogenic antibodies compared with injected C5aR /  mice as assessed by
an assay for MPO performed with protein extracts from five joints each from
C5aR /  and C5aR /  mice 14 d after mAb transfer (P   0.005). (C) Neutro-
philia (N) in arthritic C5aR /  joints (top) is evident from examination of high
powered fields of tissue sections stained with H&E. In contrast, only rare neutro-
phils were observed in joints from C5aR /  animals 14 d after mAb transfer.
Arrowheads indicate region of lower power fields (left) enlarged in the high
power fields (right). Cartilage (C), pannus (P), and synovial lining (S) are indicated.1469 Grant et al.
indicating a reduction in the recruitment of neutrophils
into the joint as a consequence of C5aR deletion (Fig. 4
B). The decreased MPO enzyme levels reflect the pro-
found reduction in the numbers of neutrophils present in
the joints from C5aR /  animals as is readily observed in
joint sections at high magnification (Fig. 4 C).
Reduced Induction of Adhesion Molecule Expression in the
Joints of C5aR-deficient Mice. One mechanism by which
proinflammatory cytokines and chemokines recruit leuko-
cytes into the inflamed joint is through the induction of
adhesion molecules on local endothelium and synovial fibro-
blasts themselves. intercellular adhesion molecule (ICAM)-1,
vascular cell adhesion molecule (VCAM)-1, and E-selec-
tin are three of the principal adhesion receptors known to
be up-regulated during the course of arthritis. Therefore,
we measured the quantitative induction of mRNA for
these three molecules in C5aR /  and wild-type mice dur-
ing arthritogenesis. Each of these adhesion molecules was
substantially up-regulated in joints from wild-type animals.
However, in joints from C5aR /  mice, VCAM-1 and
E-selectin mRNA levels remained at baseline levels (Fig. 4
A). A slight induction of ICAM-1 was observed in C5aR-
deficient joints, although the levels were significantly lower
than in arthritic wild-type littermates. Therefore, the in-
duction of the major adhesion molecules involved in the
extravasation and localization of inflammatory cells in the
arthritic joint is inhibited in C5aR /  mice.
Discussion
A role for the complement system in RA is suggested by
a number of observations. Perhaps foremost among these is
that rheumatoid factors, autoantibodies against the Fc por-
tion of IgG, are present in a large proportion of RA pa-
tients (11). Deposition of immune complexes in these pa-
tients, as in other autoimmune diseases such as SLE, would
lead to activation of the complement system. This activa-
tion would be manifested in the proinflammatory effects of
anaphylatoxins C3a and C5a and complement receptor-
mediated cellular activation by C3b and other proteins in
the pathway. In fact, elevated levels of C3a and C5a have
been noted in the synovial fluid and peripheral blood of
RA patients (19–21). Additionally, other cell surface and
soluble proteins relevant to complement system activation
and control are induced in RA, such as the increased ex-
pression of CD55 in the intimal layer of inflamed synovia
and the increased circulating C-reactive protein levels in
the peripheral blood of RA patients (22). These findings
point toward a hyperactivity of the complement and innate
immune system pathways in human RA, perhaps indicative
of a causative or perpetuating role for these systems in
chronic joint inflammation.
The principal mouse models of arthritis, such as CIA and
the passive antibody transfer model, also have clear anti-
body and complement-driven components. Although col-
lagen is the principal self-antigen for these models, it has
recently become clear that other autoantibody targets such
as GPI can substitute as initiating factors in experimental
arthritis (23). Therefore, as autoreactive immune com-
plexes form and are deposited in healthy joint tissue, the
complement cascade is activated leading to the liberation of
C5a. Our findings indicate that subsequent C5a-dependent
recruitment of neutrophils and other cells via interaction
with the C5aR is a crucial step in the cascade of events
leading to the arthritic environment in the joint. It has
been shown that anticollagen antibodies become deposited
in the joint and activate complement in the absence of C5
(24). Here, we demonstrate that anticollagen antibodies
traffic to the joints of C5aR /  mice and are deposited on
articular cartilage. Furthermore, we show that in this
model, antibody deposition in the joint is associated with
the presence of complement components C3 and C1q,
which are also detected on the cartilage surface. Therefore,
the failure of C5aR /  mice to develop arthritis after anti-
collagen antibody transfer does not reflect reduced anti-
body deposition and consequent complement activation,
but rather indicates a failure of C5aR-expressing cell popu-
Figure 5. Model for the inflammatory cascade of arthritis. After the
initiation of disease as a result of the activation of autoreactive T and B
cells, rheumatoid factor and other autoantibodies are produced and de-
posited in the joint spaces. Immune complex formation leads to the acti-
vation of the complement cascade, ultimately yielding C5a. The C5a gra-
dient emanating from the joint recruits and activates neutrophils and
monocytes to the synovium and synovial fluid. In addition, C5a may di-
rectly activate endothelial cells to up-regulate adhesion receptor expres-
sion, promoting extravasation of inflammatory cells. Activated neutro-
phils liberate additional chemotactic factors that recruit additional
inflammatory cell subsets, particularly monocyte/macrophage lineage
cells. These latter cells, a primary source of TNF  and IL-1 , activate res-
ident synovial fibroblasts. Activated synovial fibroblasts produce additional
effector molecules, including cytokines, chemokines, and proteases. The
end result is a cycle of positive feedback that amplifies the inflammation
and results in cartilage and bone degradation.1470 The C5a Receptor Is Essential for the Effector Phase of Experimental Arthritis
lations to respond to those events. Data published while
this report was in preparation suggest that in a model of ar-
thritis induced by the transfer of antibodies against the
ubiquitous enzyme GPI, the classical pathway of comple-
ment activation is dispensable (25). It is possible that there
are fundamental mechanistic differences between anti-CIA
and anti-GPI–induced disease. Alternatively, both models
may activate the classical pathway as manifest by C1q dep-
osition on articular cartilage, but the alternative pathway
can compensate in its absence.
In contrast to C5aR, targeted disruption of C3aR ex-
pression had no discernible effect on the induction of ar-
thritis induced by anticollagen mAbs. This difference points
toward neutrophil recruitment as an important component
of arthritogenesis in this model because C3aR protein ex-
pression is much lower than C5aR on neutrophils and does
not appear to substantially induce chemotaxis of this cell
type (26–28). Here, we demonstrate that neutrophils, T
cells, and macrophages are not recruited in the absence of
the C5aR during arthritis induction in a model that by-
passes the stage of antigen-specific T and B cell develop-
ment. In addition, MIP-1 , MIP-2, and ENA-78 are not
induced in the absence of the C5aR. Therefore, in this an-
imal model, C5a-dependent stimulation of leukocytes, en-
dothelial cells, or other cell types leads to the production of
chemokines and proinflammatory mediators that contrib-
ute to the disease process. The adhesion molecules
VCAM-1, ICAM-1, and E-selectin, which are induced in
wild-type mice during arthritogenesis and believed to play
important roles in the extravasation of inflammatory cells
into the arthritic joint, are not induced in the absence of
the C5aR. Because the C5aR is expressed on endothelial
cells, signaling through this receptor may lead to the up-
regulation of adhesion receptors important for the extrava-
sation of inflammatory cells. Alternatively, factors produced
by C5aR  neutrophils and monocytes might be required
for the induction of adhesion receptors on the endothe-
lium. Our findings suggest that neutrophilia is a critical
early event in the initiation of disease in this model and that
in the absence of the C5aR, neutrophils are not recruited
to sites of immune complex deposition and complement
activation. Therefore, production of chemokines and other
effector molecules by neutrophils might be essential for the
recruitment of other inflammatory cells and the subsequent
chronic stage of arthritis (Fig. 5). Consistent with this inter-
pretation, it was recently reported that depletion of neutro-
phils prevented the induction of arthritis in the K/BxN se-
rum transfer model and depletion of neutrophils after
disease initiation led to an amelioration of joint damage and
inflammation (29).
Beyond the profound inhibition of inflammation, we
observed no signs of cartilage and bone degradation in
C5aR /  mice. Joint histology of C5aR /  animals after
arthritogenic mAb transfer was indistinguishable from naive
joints. At the molecular level, we observed a complete in-
hibition of induction of a key cartilage-degrading enzyme,
MMP-3. In addition, OPGL expression in the joints of
C5aR /  mice remained at baseline levels, reflecting a fail-
ure to activate a key pathway believed to regulate osteo-
clastogenesis and bone resorption in arthritis (30, 31).
Therefore, the deposition of autoantibodies and resulting
activation of the complement cascade do not provide the
signals necessary to progress to joint degradation in the ab-
sence of recruited inflammatory cells.
A variety of mouse strains, including NOD, are C5 defi-
cient due to a genetic deletion encompassing a portion of
the gene encoding this component of the complement cas-
cade. These strains are resistant to arthritis induced by col-
lagen and anti–glucose-6-phosphate autoantibodies (24, 32,
33). A role for C5 in arthritis is further supported by the
observation that an anti-C5 antibody prevented CIA and
ameliorated established disease (34). More recently, clinical
trials with anti-C5 antibodies have been initiated to treat
human RA. However, the mechanistic basis for resistance
of C5-deficient mice to disease has never been delineated.
The activation of the complement cascade as a result of
deposition of anticollagen antibodies in the joint would
lead to the liberation of C5a and the recruitment or activa-
tion of C5aR-bearing cells. In addition, the cleavage of C5
results in the formation of C5b and recruitment of addi-
tional components of the complement cascade, ultimately
resulting in the formation of the membrane attack complex
(MAC). The formation of the MAC in the joint could re-
sult in the necrosis of local cells and nonlytic effects of the
MAC, such as induction of inflammatory mediator release
and cellular proliferation, both of which could contribute
to the arthritic condition. Our results indicate that the pro-
tective effect of C5 deficiency can be explained as an in-
ability to form C5a and recruit and/or activate cells
through the C5aR. Although it seems from our results that
MAC-dependent processes are insufficient to cause arthritis
in this model, we cannot exclude the possibility that C5b-
dependent processes exacerbate disease. Given the extent
to which arthritis is inhibited in an effector model of arthri-
tis, novel inhibitors or biotherapeutics directed against the
C5aR may show promise in the treatment of human RA.
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